{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T15:27:26Z","timestamp":1772206046460,"version":"3.50.1"},"reference-count":86,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.beha.2009.06.001","type":"journal-article","created":{"date-parts":[[2009,12,2]],"date-time":"2009-12-02T10:19:00Z","timestamp":1259749140000},"page":"409-429","source":"Crossref","is-referenced-by-count":41,"title":["Management of Drug Toxicities in Chronic Myeloid Leukaemia"],"prefix":"10.1016","volume":"22","author":[{"given":"Michael J.","family":"Mauro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.beha.2009.06.001_bib1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.beha.2009.06.001_bib2","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients","volume":"22","author":"Peng","year":"2004","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2009.06.001_bib3","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2009.06.001_bib4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood-2003-01-0025","article-title":"Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha","volume":"102","author":"Cortes","year":"2003","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2009.06.001_bib5","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.06.001_bib6","article-title":"First report of the TOPS study: a randomized Phase III trial of 400 mg vs 800 mg imatinib in patients with newly diagnosed, previously untreated CML in chronic phase using molecular endpoints","volume":"93","author":"Cortes","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2009.06.001_bib7","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.429.429","article-title":"Correlation of pharmacokinetic data with cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib - an analysis of IRIS study data","volume":"108","author":"Larson","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2009.06.001_bib8","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.06.001_bib9","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.2141.2141","article-title":"Trough plasma imatinib concentrations are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"108","author":"Picard","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2009.06.001_bib10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.leukres.2008.07.015","article-title":"Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels","volume":"33","author":"Forrest","year":"2009","journal-title":"Leuk Res"},{"issue":"8","key":"10.1016\/j.beha.2009.06.001_bib11","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.leukres.2009.02.030","article-title":"Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia","volume":"33","author":"Mahon","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2009.06.001_bib12","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.4820.4820","article-title":"Therapeutic drug monitoring of imatinib and impact on clinical decision making","volume":"108","author":"Blasdel","year":"2006","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.beha.2009.06.001_bib13","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.beha.2009.06.001_bib14","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.beha.2009.06.001_bib15","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.beha.2009.06.001_bib16","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.beha.2009.06.001_bib17","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.beha.2009.06.001_bib18","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","article-title":"Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment","volume":"111","author":"Hochhaus","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2009.06.001_bib19","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3324\/haematol.2009.006999","article-title":"Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials","volume":"94","author":"Silver","year":"2009","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.beha.2009.06.001_bib20","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2009.06.001_bib21","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia","volume":"111","author":"le Coutre","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2009.06.001_bib22","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2009.06.001_bib23","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2009.06.001_bib24","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1182\/blood-2007-02-073528","article-title":"Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study","volume":"110","author":"Ottmann","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2009.06.001_bib25","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","article-title":"Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg\/day of imatinib as initial therapy","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2009.06.001_bib26","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/sj.leu.2402996","article-title":"Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa","volume":"17","author":"Marin","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.06.001_bib27","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.7063","article-title":"Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) or accelerated phase (AP)","volume":"26","author":"Jabbour","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2009.06.001_bib28","article-title":"Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP)","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.06.001_bib29","article-title":"Efficacy of nilotinib (formerly AMN107) in patients (Pts) with newly diagnosed, previously untreated philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP)","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2009.06.001_bib30","first-page":"227","article-title":"Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"88","author":"Marin","year":"2003","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.beha.2009.06.001_bib31","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1002\/cncr.20285","article-title":"Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia","volume":"100","author":"Quintas-Cardama","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2009.06.001_bib32","first-page":"139a","article-title":"Myeloid growth factors for neutropenia during imatinib mesylate (STI571) therapy for CML: preliminary evidence of safety and efficacy","volume":"98","author":"Mauro","year":"2001","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2009.06.001_bib33","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.leukres.2003.11.003","article-title":"Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia","volume":"28","author":"Ault","year":"2004","journal-title":"Leuk Res"},{"issue":"11","key":"10.1016\/j.beha.2009.06.001_bib34","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1002\/cncr.20292","article-title":"Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase","volume":"100","author":"Cortes","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2009.06.001_bib35","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2008-09-180604","article-title":"Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2009.06.001_bib36","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1200\/JCO.2003.11.143","article-title":"Practical management of patients with chronic myeloid leukemia receiving imatinib","volume":"21","author":"Deininger","year":"2003","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.beha.2009.06.001_bib37","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1158\/1078-0432.CCR-08-0308","article-title":"Tasigna for chronic and accelerated phase Philadelphia chromosome\u2013positive chronic myelogenous leukemia resistant to or intolerant of imatinib","volume":"14","author":"Hazarika","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.beha.2009.06.001_bib38","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/1078-0432.CCR-07-4175","article-title":"Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate","volume":"14","author":"Brave","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"25","key":"10.1016\/j.beha.2009.06.001_bib39","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure","volume":"25","author":"Quint\u00e1s-Cardama","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2009.06.001_bib40","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2008.07108.x","article-title":"Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis","volume":"141","author":"de Lavallade","year":"2008","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.beha.2009.06.001_bib41","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","article-title":"Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy","volume":"23","author":"Mustjoki","year":"2009","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2009.06.001_bib42","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1200\/JCO.2003.01.052","article-title":"Uncommon syndromes and treatment manifestations of malignancy: case 4. Periorbital edema and imatinib mesylate therapy for chronic myelogenous leukemia","volume":"21","author":"Ramar","year":"2003","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2009.06.001_bib43","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/cncr.10729","article-title":"Severe periorbital edema secondary to STI571 (Gleevec)","volume":"95","author":"Esmaeli","year":"2002","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.beha.2009.06.001_bib44","first-page":"228","article-title":"Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate","volume":"5","author":"Scheinfeld","year":"2006","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"10.1016\/j.beha.2009.06.001_bib45","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJM200208083470614","article-title":"Imatinib mesylate and gray hair","volume":"347","author":"Etienne","year":"2002","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.beha.2009.06.001_bib46","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1002\/cncr.11812","article-title":"Imatinib mesylate causes hypopigmentation in the skin","volume":"98","author":"Tsao","year":"2003","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.beha.2009.06.001_bib47","first-page":"979","article-title":"The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations","volume":"87","author":"Marin","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2009.06.001_bib48","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa051140","article-title":"Altered bone and mineral metabolism in patients receiving imatinib mesylate","volume":"354","author":"Berman","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2009.06.001_bib49","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/ajh.20778","article-title":"Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukaemia in late chronic phase, and this effects is associated with response","volume":"82","author":"Osorio","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2009.06.001_bib50","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1056\/NEJMc062388","article-title":"Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism","volume":"355","author":"Grey","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.06.001_bib51","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1182\/blood-2007-07-104281","article-title":"Long-term imatinib therapy promotes bone formation in CML patients","volume":"111","author":"Fitter","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2009.06.001_bib52","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3324\/haematol.12373","article-title":"Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia","volume":"93","author":"Jonsson","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2009.06.001_bib53","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1359\/jbmr.070719","article-title":"Imatinib promotes osteoblast differentiation by inhibiting PDGFR signalling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms","volume":"22","author":"O'Sullivan","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.beha.2009.06.001_bib54","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1182\/blood-2005-09-3568","article-title":"Imatinib as a potential antiresorptive therapy for bone disease","volume":"107","author":"Dewar","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.06.001_bib55","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2006.09.007","article-title":"Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity","volume":"551","author":"El Hajj Dib","year":"2006","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.beha.2009.06.001_bib56","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ajh.20486","article-title":"Imatinib mesylate as a cause of acute liver failure","volume":"81","author":"Cross","year":"2006","journal-title":"Am J Hematol"},{"issue":"48","key":"10.1016\/j.beha.2009.06.001_bib57","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v13.i48.6608","article-title":"Imatinib-induced fatal acute liver failure","volume":"13","author":"Ridruejo","year":"2007","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.beha.2009.06.001_bib61","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1200\/JCO.2007.11.0304","article-title":"Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group","volume":"26","author":"Ramanathan","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2009.06.001_bib62","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.2007.13.3819","article-title":"Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group","volume":"26","author":"Gibbons","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2009.06.001_bib63","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1182\/blood-2002-02-0518","article-title":"Binding of imatinib by alpha(1)-acid glycoprotein","volume":"100","author":"Gambacorti-Passerini","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2009.06.001_bib64","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/sj.bjc.6601152","article-title":"Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia","volume":"89","author":"O'Brien","year":"2003","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.beha.2009.06.001_bib65","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/j.1365-2125.2008.03150.x","article-title":"Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia","volume":"65","author":"Wang","year":"2008","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.beha.2009.06.001_bib66","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1124\/jpet.103.055574","article-title":"Interaction of imatinib mesilate with human P-glycoprotein","volume":"307","author":"Hamada","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"10.1016\/j.beha.2009.06.001_bib67","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1211\/jpp.58.7.0016","article-title":"Effect of imatinib mesilate on the disposition kinetics of ciclosporin in rats","volume":"58","author":"Kajita","year":"2006","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.beha.2009.06.001_bib68","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2210-7-13","article-title":"Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and\/or ifosfamide","volume":"7","author":"Rezai","year":"2007","journal-title":"BMC Pharmacol"},{"issue":"10","key":"10.1016\/j.beha.2009.06.001_bib69","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.leukres.2008.01.015","article-title":"Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib","volume":"32","author":"Breccia","year":"2008","journal-title":"Leuk Res"},{"issue":"8","key":"10.1016\/j.beha.2009.06.001_bib70","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkela","year":"2006","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.beha.2009.06.001_bib71","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood-2007-01-070144","article-title":"Congestive heart failure is a rare event in patients receiving imatinib therapy","volume":"110","author":"Atallah","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2009.06.001_bib72","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/nm0107-14","article-title":"In reply to \u2018Cardiotoxicity of the cancer therapeutic agent imatinib mesylate\u2019","volume":"13","author":"Atallah","year":"2007","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.beha.2009.06.001_bib73","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nm0107-13a","article-title":"In reply to \u2018Cardiotoxicity of the cancer therapeutic agent imatinib mesylate\u2019","volume":"13","author":"Hatfield","year":"2007","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.beha.2009.06.001_bib74","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ejca.2007.01.018","article-title":"Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005","volume":"43","author":"Verweij","year":"2007","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.beha.2009.06.001_bib76","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","article-title":"The effects of imatinib on pregnancy outcome","volume":"111","author":"Pye","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2009.06.001_bib77","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/annonc\/mdj065","article-title":"Pregnancy on imatinib: fatal outcome with meningocele","volume":"17","author":"Choudhary","year":"2006","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.beha.2009.06.001_bib78","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.leukres.2005.01.009","article-title":"Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML). Outcome of discontinuation of imatinib therapy after achieving a molecular remission","volume":"29","author":"Ali","year":"2005","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.beha.2009.06.001_bib79","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-0609.2005.00420.x","article-title":"Imatinib in pregnancy","volume":"74","author":"AlKindi","year":"2005","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.beha.2009.06.001_bib80","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00404-007-0547-6","article-title":"Pregnancy complicated with chronic myelogeneous leukemia (CML) successfully treated with imatinib: a case report","volume":"278","author":"Buyukbayrak","year":"2008","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"10.1016\/j.beha.2009.06.001_bib81","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.3324\/haematol.10935","article-title":"Two successful pregnancies in a chronic myeloid leukemia patient treated with imatinib","volume":"92","author":"Garderet","year":"2007","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.beha.2009.06.001_bib82","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/10428190310001645195","article-title":"Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib","volume":"45","author":"Heartin","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.beha.2009.06.001_bib83","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1093\/annonc\/mdi398","article-title":"Pregnancy outcome of two patients treated with imatinib","volume":"16","author":"Prabhash","year":"2005","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.beha.2009.06.001_bib84","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.jp.7211665","article-title":"Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk","volume":"27","author":"Russell","year":"2007","journal-title":"J Perinatol"},{"key":"10.1016\/j.beha.2009.06.001_bib85","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1182\/blood-2006-10-051391","article-title":"Imatinib concentrations in human milk","volume":"109","author":"Gambacorti-Passerini","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.06.001_bib86","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.3230.3230","article-title":"Pregnancy outcomes among patients with chronic myeloid leukemia treated with Dasatinib","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2009.06.001_bib87","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1124\/dmd.108.022764","article-title":"Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats","volume":"36","author":"He","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.beha.2009.06.001_bib88","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","article-title":"Discontinuation of imatinib therapy after achieving a molecular response","volume":"104","author":"Cortes","year":"2004","journal-title":"Blood"},{"issue":"2 Suppl. 2","key":"10.1016\/j.beha.2009.06.001_bib89","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/shem.2003.50038","article-title":"Imatinib treatment: specific issues related to safety, fertility, and pregnancy","volume":"40","author":"Hensley","year":"2003","journal-title":"Semin Hematol"},{"issue":"7","key":"10.1016\/j.beha.2009.06.001_bib90","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1200\/JCO.2005.04.6557","article-title":"Pregnancy among patients with chronic myeloid leukemia treated with imatinib","volume":"24","author":"Ault","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692609000334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692609000334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T00:59:30Z","timestamp":1590281970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692609000334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S1521692609000334"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2009.06.001","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}